Novo Nordisk A/S
This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.
This active surveillance program will monitor for any signal indicating a possible association between treatment with long-acting GLP-1 RAs and the development of MTC in the United States population. Given the very low incidence of MTC in the general population, the expected rate of exposure to long-acting GLP-1 RAs, the anticipated long latency of the potential outcome under study and the limited data on underlying risk factors for development of MTC other than RET proto-oncogene mutations, an active surveillance program is the most efficient means of identifying a possible association betwee…
Inclusion Criteria: * A record of medullary thyroid carcinoma (MTC) identified from state/regional population-based cancer registries * At least 18 years or older. There are no other inclusion or exclusion criteria.
None. Non-interventional study.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.